Journals / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 11

Prognostic value of neutrophil-to-lymphocyte ratio in patients undergoing curative surgical resection for hepatocellular carcinoma

Pages
2926–2932
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall survival time was found to be lower in Group 2 compared to Group 1 (171 vs 106 months p:0.033).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: the purpose of this study is to determine the prognostic value of the preoperative Neutrophil-to-Lymphocyte ratio (NLR) inpatients who underwent curative surgical treatment for hepatocellular carcinoma (HCC).Materials and Methods: Patients who underwent curative resection for HCC between 2004 and 2015 were included in the study.Patients were divided into two groups based on the cut-off value: Group 1 (NLR low) and Group 2 (NLR elevated).
📊
Key Findings & Data:Demographics andclinical characteristics, tumor characteristics, and mean survival of patients were compared between the groups.Results: 41 patients were included in our study and Group 1 (NLR low) consisted of (n:11) patients; Group 2 (NLR elevated) consistedof (n:30) patients based on a cut-off value of 2.43.
💡
Conclusion & Impact:Overall survival time was found to be lower in Group 2 compared to Group 1 (171 vs 106 months p:0.033).
🔬Design:Research Article
📍Scope:2004 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: the purpose of this study is to determine the prognostic value of the preoperative Neutrophil-to-Lymphocyte ratio (NLR) inpatients who underwent curative surgical treatment for hepatocellular carcinoma (HCC).Materials and Methods: Patients who underwent curative resection for HCC between 2004 and 2015 were included in the study.Patients were divided into two groups based on the cut-off value: Group 1 (NLR low) and Group 2 (NLR elevated). Demographics andclinical characteristics, tumor characteristics, and mean survival of patients were compared between the groups.Results: 41 patients were included in our study and Group 1 (NLR low) consisted of (n:11) patients; Group 2 (NLR elevated) consistedof (n:30) patients based on a cut-off value of 2.43. The number of males was higher in both groups (90.9% vs 90%, p:0.712). TheChild-Plug class A was the most common one in both groups (81.8%vs76.7%, p:0.680). HBV infection was the most commonetiological cause (81.8% vs 53.3%, p:0.344). Lesions were predominantly located in the right lobe (63.6% vs 66.7%, p:0.568). The totaltumor diameter was similar (6.56 cm vs 8.69 cm, p:0.258). In the multivariate analysis for survival, tumor diameter greater than 5cm (HR 1.412 95% - Cl0.345-5.780, p:0.018) and NLR higher than 2.43 (HR 0.100 95% -Cl 0.011-0.882, p:0.038) were independentrisk factors. Overall survival time was found to be lower in Group 2 compared to Group 1 (171 vs 106 months p:0.033). Disease-freesurvival rates were similar in the groups (37 vs 43 months, p:0.485).Conclusion: Although the elevated NLR level was found to be a risk factor for decreased overall survival in our study, this was notrelated to clinicopathological variables.

🔖

Cite This Article

TOPAL, U., SARITAŞ, A. G., ERAY, İ. C., ÜLKÜ, A., DALCI, K., AKÇAM, A. T. (2022). Prognostic value of neutrophil-to-lymphocyte ratio in patients undergoing curative surgical resection for hepatocellular carcinoma. Annals of Medical Research, Cilt: 27 - Sayı: 11, 2926–2932. https://ajindex.com/articles/446247

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Villanueva A. Hepatocellular Carcinoma. N Engl J Med 2019;380:1450-62
  2. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CACancer J Clin 2015;65:87-108 3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30
  3. European Association For The Study Of The Liver, European Organisation For Research, Treatment Of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43
  4. Jia X, Liu J, Gao Y, et al. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with metaanalysis. Arch Med Res 2014;45:580-8
  5. Zhang JF, Shu ZJ, Xie CY, et al. Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. PloS One. 2014;9:8818 7. Wang D, Bai N, Hu X, et al Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC PeerJ 2019;7:7132
  6. Yalav O, Topal U, Unal AG, et al Clinical Value of Neutrophil/Lymphocyte Ratio in Predicting Postoperative Complications and Prognosis in Patients with Colorectal Cancer Undergoing Surgical Treatment. Turk J Colorectal Dis 2020;30:49-56
  7. Yalav O, Topal U, Unal AG. Clinical value of neutrophil/ lymphocyte ratio in predicting postoperative complications, lymph node positivity and prognosis in gastric cancer patients who underwent curative surgical resection. Ann Med Res 2019;26:2513-9
  8. Arikan TB, Sozuer EM, Topal U, et al. The value and prognostic significance of neutrophil / lymphocyte ratio in predicting pancreatic fistula in patients undergoing pancreaticoduodenectomy for periampullary tumors Ann Med Res 2020;27:1214-2
  9. Dal F, Topal U, Sozuer EM, et al. Prognostic significance of the neutrophil to lymphocyte ratio in patients with curative resection of esophageal cancer: a single center experience Ann Ital Chir Digital Edition 2020;9:1-7
  10. ShirakiT, IshizukaM, Kubota K, et al. An elevated neutrophil-to-lymphocyte ratio predicts a poor postoperative survival in primary hepatocellular carcinoma patients with a normal preoperative serum level of alpha-fetoprotein. Surgery Today 2019;49:661-9
  11. Gao F, Li X, Geng M, et al. Pretreatment neutrophil– lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma. Medicine 2015;94:639
  12. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Ce